Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

HC Wainwright gives Septerna a Buy rating and $26 price target citing multiple upcoming catalysts. Septerna trades below cash value despite a Novo Nordisk partnership and a promising drug pipeline.

Novo also recently partnered with another biotech start-up, Septerna, to develop small molecules for weight loss and metabolic disorders. That collaboration is worth up to $2.2 billion between up ...

Investors were disappointed when Novo Nordisk A/S (NYSE:NVO)’s next-generation obesity medication, CagriSema, which was supposed to emerge in 2026, failed to achieve the weight loss goals they ...

Novo Nordisk's stock is still up more than 250% since Jørgensen took over as CEO in January 2017. But shares of Eli Lilly have gained about 800% since that same month, when CEO Dave Ricks took ...

Septerna’s stock jumped 69% in premarket trading after the deal was announced. Novo Nordisk’s stock rose 1.2% in European trading. The Mayo Clinic has more on prescription weight-loss drugs.

HealthDay News — Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, type 2 diabetes and other metabolic diseases.

Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company’s innovative ...

Septerna's Novo Nordisk deal secures $195M upfront, with over $2B potential. Read why SEPN is a market opportunity, as it trades over a 20% discount.